Stocks Health care GNTA

NASDAQ · Health care

Genenta Science S.p.A. (GNTA)

It posted a net loss of €6.5M. In fiscal 2025 capital spending exceeded operating cash flow by €6.9M. At December 31, 2025 it held €5.5M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 1, 2026.

What Genenta Science S.p.A. does

Genenta Science S.p.A. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker GNTA.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Latest SEC filings

What Genenta Science S.p.A. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 11, 2026
   Foreign issuer update 6-K
2. September 2, 2026
   Foreign issuer update 6-K
3. July 31, 2026
   Foreign issuer update 6-K
4. July 14, 2026
   Foreign issuer update 6-K
5. July 1, 2026
   Foreign issuer update 6-K
6. June 26, 2026
   Foreign issuer update 6-K
7. June 24, 2026
   Foreign issuer update 6-K
8. June 17, 2026
   Foreign issuer update 6-K
9. June 16, 2026
   Foreign issuer update 6-K
10. May 29, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on May 5, 2026. Insider transactions on SEC

Insider trades

What the people running Genenta Science S.p.A. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about GNTA

What does Genenta Science S.p.A. do?

Genenta Science S.p.A. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker GNTA.

Is Genenta Science S.p.A. profitable?

No. In fiscal 2025 it reported a net loss of €6.5M.

When did Genenta Science S.p.A. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 1, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 11, 2026.

Similar companies

Compare GNTA with

Compare GNTA with any company

Follow GNTA

Get an email when Genenta Science S.p.A. files with the SEC: results, executive changes, material agreements and annual reports.

Follow GNTA: get an email when it files

Where the numbers come from

Financial figures are the values Genenta Science S.p.A. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.